Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
about
Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer MetabolismNovel actions of next-generation taxanes benefit advanced stages of prostate cancer.Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats.Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer GrowthInhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer.Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.Current approaches to incorporation of radium-223 in clinical practice.Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment.Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
P2860
Q26774456-A61B2226-E997-410D-93AA-23391178D9A5Q35099127-DF4736BA-E649-4CF3-9C6E-CA52F8B8DBB8Q35110884-DD7E9DED-1799-4931-A95B-7AAC6F5CF1B5Q35809973-ED340AB1-1261-4793-9663-0BB3DFEB99B6Q35982218-27958828-A211-4786-87A3-DFB549108B4BQ37317305-95CFEF87-9D5B-47F4-B8D8-D3F08C94DCCBQ37597690-86B60689-F0E9-442D-92AD-5B1122AE1372Q38620751-F8131F7F-CF1D-4C23-856E-E23651E983B1Q38750965-178808C0-3A8D-47D2-BE3C-2E68F1DBA5C7Q38865487-3AA0AD1A-32CE-40CB-8254-C7CA72B735E7Q39001530-08F52C2F-9E1A-428A-B37E-56AA5E05FDCBQ47212646-973B0639-F8F5-407D-8094-4ED79DBDA761Q53817267-3FF8B6EB-D063-4F7D-B5F0-AF937EE303A7Q57110000-EBCC199D-5C75-498A-BE10-C40DC958208E
P2860
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@ast
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@en
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@nl
type
label
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@ast
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@en
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@nl
prefLabel
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@ast
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@en
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@nl
P2093
P2860
P3181
P356
P1476
Sequential use of novel therap ...... llowing docetaxel chemotherapy
@en
P2093
S. Gillessen Sommer
P2860
P3181
P356
10.1177/1756287213509677
P407
P577
2014-02-01T00:00:00Z